IL-1Ra
Phase 2Small molecule
IL-1Ra is one of 29 small molecule programs targeting Corneal Neovascularization. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
IL-1Ra
UUniversity of Manchester
Phase 2
Inderal
WWyeth-Lederle Vaccines
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Sulfonylureas
Eli LillyPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Sglt2i
UUniversity of Chicago
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Adult Subject1 trial
Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
Unknown status·—·Phase 1·NCT03383276·34 enrolled
Interleukin1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IL-1Ra. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Manchester